The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus Intracoronary (Q33572281)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus Intracoronary	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus Intracoronary (English)

1 reference

Europe PubMed Central

28 July 2017

author name string

Allan Iversen

1

1 reference

Europe PubMed Central

28 July 2017

Søren Galatius

2

1 reference

Europe PubMed Central

28 July 2017

Jan S Jensen

3

1 reference

Europe PubMed Central

28 July 2017

publication date

1 November 2008

1 reference

Europe PubMed Central

28 July 2017

Current cardiology reviews

1 reference

Europe PubMed Central

28 July 2017

4

1 reference

Europe PubMed Central

28 July 2017

4

1 reference

Europe PubMed Central

28 July 2017

293-299

1 reference

Europe PubMed Central

28 July 2017

Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801861

21 June 2018

Rationale for intracoronary administration of abciximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801861

21 June 2018

Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801861

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801861

21 June 2018

A perspective on the toxicological mechanisms possibly contributing to the failure of oral glycoprotein IIb/IIIa antagonists in the clinic

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801861

21 June 2018

Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801861

21 June 2018

An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801861

21 June 2018

Abciximab readministration: results of the ReoPro Readministration Registry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801861

21 June 2018

Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801861

21 June 2018

Severe delayed thrombocytopenia associated with abciximab (ReoPro) therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801861

21 June 2018

Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801861

21 June 2018

Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801861

21 June 2018

Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801861

21 June 2018

Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801861

21 June 2018

Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801861

21 June 2018

Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801861

21 June 2018

Acute profound thrombocytopenia without bleeding complications after abciximab administration.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801861

21 June 2018

Efficacy of abciximab readministration in coronary intervention.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801861

21 June 2018

Bleeding complications of glycoprotein IIb-IIIa receptor inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801861

21 June 2018

Bleeding complications with platelet glycoprotein IIb/IIIa receptor antagonists.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801861

21 June 2018

Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801861

21 June 2018

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801861

21 June 2018

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801861

21 June 2018

Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801861

21 June 2018

Abciximab-associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801861

21 June 2018

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801861

21 June 2018

Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801861

21 June 2018

Role of platelets in the development of atherosclerotic disease and possible interference with platelet inhibitor drugs.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801861

21 June 2018

The pathogenesis of coronary artery disease and the acute coronary syndromes (1).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801861

21 June 2018

Intracoronary application of abciximab in patients with ST-elevation myocardial infarction.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801861

31 October 2018

The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: insights from a large regional registry of contemporary percutaneous coronary intervention

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801861

31 October 2018

One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801861

31 October 2018

Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801861

31 October 2018

Comparison of intracoronary vs. intravenous administration of abciximab in coronary stenting

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801861

31 October 2018

A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801861

31 October 2018

Extensive thrombus prior to elective percutaneous coronary intervention.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801861

31 October 2018

Instant dissolution of intracoronary thrombus by abciximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A sequential approach to the management of a massive intracoronary thrombus in ST elevation myocardial infarction: a case report

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safe use of platelet GP IIb/IIIa inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Angioscopic evaluation of site-specific administration of ReoPro

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Compl

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Angiographic evaluation of the effect of intracoronary abciximab administration in patients undergoing urgent PCI

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of platelet deposition and lysis of intracoronary thrombus during balloon angioplasty using urokinase-coated hydrogel balloons

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro evaluation of c7E3-Fab (ReoPro) eluting polymer-coated coronary stents

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduced thrombus burden with abciximab delivered locally before percutaneous intervention in saphenous vein grafts

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Successful dissolution of occlusive coronary thrombus with local administration of abciximab during PTCA

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and efficacy of the platelet glycoprotein IIb/IIIa inhibitor abciximab in Chinese patients undergoing high-risk angioplasty

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intracoronary heparin delivery in humans. Acute feasibility and long-term results

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2174/157340308786349480

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33572281&oldid=1970958659"